It offers clear environmental benefits, lower emissions, reduced hazardous material use, and alignment with circular economy goals
The trial is the largest to date evaluating Leqvio and the first to focus on patient-centered outcomes
First Indian company to follow global recommendations in accordance with the World Health Organisation (WHO)
The positive benefit-risk profile of vericiguat in its approved indication in patients with HFrEF following a recent heart failure event based on the pivotal Phase III VICTORIA trial remains unchanged
Zilebesiran, a potential best-in-disease RNAi anti-hypertensive with twice-yearly subcutaneous dosing, demonstrated encouraging safety when combined with two or more antihypertensives
Nuvaxovid is the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. for the 2025-2026 vaccination season
Treatment with Verzenio also resulted in sustained invasive disease-free survival and distant relapse-free survival benefit
Triggering global regulatory submissions this year for the treatment of obesity
The updated formula for Spikevax is now approved for individuals 6 months through 64 years of age
With the addition of Phase II (~91 KL) in Q1 FY26, the combined capacity of the block now stands at ~200 KL
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
